| Literature DB >> 32832576 |
Akane Takamatsu1,2, Kenta Yao1, Shutaro Murakami2, Yasuaki Tagashira1,2, Shinya Hasegawa1,2, Hitoshi Honda1,2.
Abstract
BACKGROUND: Postprescription review and feedback (PPRF) is one of the most common strategies in antimicrobial stewardship program (ASP) intervention. However, disagreements between the prescribers and ASP personnel can occur. The aim of the present study was to identify the factors associated with nonadherence to PPRF intervention.Entities:
Keywords: adherence; antimicrobial stewardship program; audit and feedback; broad-spectrum antimicrobials; postprescription review and feedback
Year: 2020 PMID: 32832576 PMCID: PMC7434090 DOI: 10.1093/ofid/ofaa298
Source DB: PubMed Journal: Open Forum Infect Dis ISSN: 2328-8957 Impact factor: 3.835
Clinical Characteristics
| Characteristics | Nonadherence | Adherence |
|
|---|---|---|---|
| Patient Demographics | |||
| Age, median (IQR), years | 68 (59–79) | 71 (59–80) | .546 |
| Male sex, n (%) | 26 (59.1) | 74 (56.1) | .861 |
| Charlson Comorbidity Index Score, n (%) | .128 | ||
| <2 | 5 (11.4) | 34 (35.8) | |
| 2–5 | 30 (68.2) | 78 (59.1) | |
| >5 | 9 (20.5) | 20 (15.2) | |
| Diabetes mellitus, n (%) | 8 (18.2) | 30 (22.7) | .673 |
| Liver disease, n (%) | 5 (11.4) | 27 (20.5) | .258 |
| Residential status before admission, n (%) | .362 | ||
| Home | 36 (81.8) | 109 (82.6) | |
| Nursing home or long-term care facility | 2 (4.6) | 3 (2.3) | |
| Chronic care hospital | 2 (4.6) | 2 (1.5) | |
| Acute care hospital | 4 (9.1) | 18 (13.6) | |
| Healthcare exposure within 30 days, n (%) | 42 (95.5) | 115 (87.1) | .164 |
| History of hospitalization within 90 days, n (%) | 30 (68.2) | 52 (39.4) | .002 |
| History of chemotherapy within 28 days, n (%) | 8 (18.2) | 7 (5.3) | .013 |
| History of steroid use within 28 days, n (%) | 20 (45.5) | 21 (15.9) | <.001 |
| Any antimicrobial allergy, n (%) | 5 (11.4) | 17 (12.9) | 1.000 |
| Surgery performed before PPRF | 1 (2.3) | 36 (27.3) | <.001 |
| Chemotherapy performed before | 8 (18.2) | 23 (17.4) | 1.000 |
| Steroid use before PPRF during | 19 (43.2) | 39 (29.6) | .100 |
| HSCT performed before PPRF | 5 (11.4) | 6 (4.6) | .145 |
| History of MDRO acquisition within | 9 (20.5) | 23 (17.4) | .656 |
| Clinical and Laboratory Characteristics at the Time of PPRF | |||
| Onset, n (%) | .141 | ||
| Community, nonhealthcare-associated | 14 (31.8) | 23 (17.4) | |
| Community, healthcare-associated | 5 (11.4) | 18 (13.6) | |
| Nosocomial | 25 (56.8) | 91 (68.9) | |
| Antimicrobial use before initiation of PPRF | 34 (77.3) | 87 (65.9) | .191 |
| Department, n (%) | .007 | ||
| Medicine | 29 (65.9) | 66 (50.0) | |
| Critical care medicine | 9 (20.5) | 16 (12.1) | |
| Surgery | 6 (13.6) | 50 (37.9) | |
| ICU stay, n (%) | 9 (20.5) | 19 (14.4) | .348 |
| Rapidly fatal McCabe score, n (%) | 21 (47.7) | 30 (22.7) | .002 |
| ANC <500 /μL, n (%) | 2 (4.6) | 6 (4.6) | 1.000 |
| WBC, median (IQR) ×103/μL | 7.9 (5.5–11.0) | 6.9 (4.2–10.8) | .474 |
| CRP, median (IQR) mg/dL | 4.6 (1.9–9.4) | 4.4 (1.5–8.9) | .709 |
| Mechanical ventilation use, n (%) | 4 (9.1) | 11 (8.3) | 1.000 |
| Vasopressor use, n (%) | 4 (9.1) | 7 (5.3) | .471 |
| Central venous catheter use, n (%) | 16 (36.4) | 41 (31.1) | .578 |
| ECMO, n (%) | 2 (4.6) | 3 (2.3) | .600 |
| Prescribers’ PGY, n (%) | .043 | ||
| 1–3 | 2 (4.6) | 25 (18.9) | |
| 4–7 | 26 (59.1) | 72 (54.6) | |
| >7 | 16 (36.4) | 35 (26.5) | |
| Male prescribers, n (%) | 34 (77.3) | 97 (73.5) | .693 |
| Prescribing decision made by, n (%) | .053 | ||
| Single physician | 32 (72.7) | 74 (56.1) | |
| Team | 12 (27.3) | 58 (43.9) |
Abbreviations: ANC, absolute neutrophil count; CRP, C-reactive protein; ECMO, extra-corporeal membrane oxygenation; HSCT, hematopoietic stem cell transplantation; ICU, intensive care unit; IQR, interquartile range; MDRO, multidrug-resistant organism; PPRF, postprescription review with feedback; PGY, postgraduate year; WBC, white blood cell.
Factors Associated With Nonadherence to PPRF Interventiona
| Variables | Univariate Analyses, OR (95% CI) |
| Multivariate Analyses, aOR (95% CI) |
|
|---|---|---|---|---|
| Charlson Comorbidity Index Score | ||||
| <2 | Ref. | |||
| 2–5 | 2.62 (0.93–7.32) | .067 | ||
| >5 | 3.06 (0.90–10.41) | .074 | ||
| History of hospitalization within 90 days | 3.30 (1.52–7.36) | .002 | 2.62 (1.18–5.81) | .018 |
| Surgery performed before PPRF during index hospitalization | 0.06 (0.01–0.47) | <.001 | ||
| Department at the Time of PPRF | ||||
| Medicine | Ref. | |||
| Critical care medicine | 1.28 (0.51–3.23) | .601 | ||
| Surgery | 0.27 (0.11–0.71) | .008 | ||
| Rapidly fatal McCabe score at the time of PPRF | 3.10 (1.42–6.75) | .002 | 2.87 (1.18–6.98) | .020 |
| Prescribers’ PGY | ||||
| 1–3 | Ref. | |||
| 4–7 | 4.5 (0.99–20.40) | .050 | ||
| >7 | 5.71 (1.20–27.11) | .028 | ||
| Prescribing decision made by single physician | 2.10 (0.94–4.85) | .053 |
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio; PGY, postgraduate year; PPRF, postprescription review with feedback; Ref., reference.
aThe Hosmer-Lemeshow test was used for goodness-of-fit for logistic regression with a P value of .38. Variables considered but not included in the multivariate analysis due to multicollinearity, and limited events were a history of chemotherapy within 28 days, history of steroid use within 28 days, and past medical history of diabetes mellitus or liver disease.
Adverse Events and Outcomes
| Variables | Nonadherence | Adherence |
|
|---|---|---|---|
| Total duration of antimicrobial therapy during index hospitalization, median (IQR) days | 16 (10–42) | 14 (10–28) | .302 |
| Total duration of PPRF antimicrobial therapy during index hospitalization, median (IQR) days | 12 (10–19) | 11 (6–16) | .063 |
| CDI developing within 3 months after PPRF, n (%) | 2 (4.6) | 3 (2.3) | .600 |
| AKI developing within 1 month after PPRF, n (%) | 12 (29.3) | 20 (16.8) | .112 |
| MDRO acquisition after PPRF during index hospitalization, n (%) | 2 (4.6) | 11 (8.3) | .522 |
| LOS from the date of PPRF to discharge, median (IQR) days | 21 (10–54) | 21 (8–43) | .637 |
| LOS from the date of admission to PPRF, median (IQR) days | 16 (8–36) | 15 (7–26) | .421 |
| In-hospital mortality, n (%) | 8 (18.2) | 19 (14.4) | .629 |
| Readmission within 1 month after discharge, n (%) | 7 (15.9) | 15 (11.4) | .436 |
Abbreviations: AKI, acute kidney injury; IQR, interquartile range; CDI, Clostridioides difficile infection; LOS, length of stay; MDRO, multidrug-resistant organism; PPRF, postprescription review with feedback.
Reasons for Nonadherence to Postprescription Review and Feedback Intervention
| Reasons | % (n = 44) |
|---|---|
| Patient-Related Factors | |
| “The patient was sick.” | 27.3% (n = 12) |
| “The patient was immunocompromised.” | 15.9% (n = 7) |
| “The patient was colonized with an MDRO.” | 9.1% (n = 4) |
| “The patient was scheduled to be transferred or discharged soon.” | 9.1% (n = 4) |
| “The patient had neutropenia.” | 2.3% (n = 1) |
| “The patient’s CRP level was high.” | 2.3% (n = 1) |
| “The patient was allergic to multiple antimicrobials.” | 2.3% (n = 1) |
| Prescriber-Related Factors | |
| “The antimicrobial seemed to be clinically effective.” | 20.5% (n = 9) |
| “I would like to continue giving antimicrobials, just in case.” | 2.3% (n = 1) |
| “The primary care provider was unavailable.” | 2.3% (n = 1) |
| Unknown | 6.8% (n = 3) |
Abbreviations: CRP, C-reactive protein; MDRO, multidrug-resistant organism.